结直肠癌是临床常见的恶性肿瘤，约25%的患者在初诊时即发现结直肠癌肝转移，其余25%～50%的患者在后续治疗过程中最终发展为肝转移。肝转移是结直肠癌患者的首要死亡原因。近年来，CRLM的多学科综合治疗理念已经成为国内外共识，但手术切除转移灶仍是目前有望治愈CRLM的惟一手段。目前，仅有10%～15%的CRLM初始可切除，其余肝转移灶为初始不可切除。因此，如何将初始不可切除CRLM转化为可切除CRLM，是当前的研究热点。本文概述了结直肠癌肝转移的治疗原则以及转化治疗策略。

Colorectal cancer is one of the most frequent malignant neoplasms.Up to 25% of patients with primary colorectal cancer have already liver metastatic disease at the time of diagnosis.Untreated patients with liver metastases share a poor prognosis with an average survival of 12 months.In contrast, patients whose metastatic lesions are surgically treated have an average 5-year survival rate of 40%.Only 10-15% of initial colorectal liver metastases are considered as being resectable.In the remaining patients, the current trend is to downstage initially unresectable metastases by neoadjuvant therapy (systemic or regional chemotherapy, portal vein embolization-PVE-or hepatic artery chemoembolization), tumor ablation and two-stage hepatectomy, alone or in combinations.This study reviews the current therapeutic options for colorectal liver metastases and their contribution to improve survival rates.